Compare Mesoblast Limited (MESO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SiTime Corporation — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while SiTime Corporation trades at $580.06 (market cap $16.63B). The key difference: SiTime Corporation is far larger — about 7.7× Mesoblast Limited's market cap, and SiTime Corporation is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SITM | |
|---|---|---|
Market Cap | $2.17B | $16.63B |
Sector | Technology | Technology |
52-Week High | $20.96 | $901.60 |
52-Week Low | $12.88 | $190.16 |
Enterprise Value | $2.17B | $15.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SITM trades at $555.15, showing minimal daily movement with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth and completed the acquisition of Renesas' timing business, but faces negative net income margins and high valuation multiples. Analyst consensus remains strongly bullish with a $825 price target, highlighting growth potential from AI infrastructure demand.
The outlook is mixed: robust revenue growth and strategic acquisitions support long-term potential, but profitability challenges and bearish technical indicators present near-term risks. Investors should weigh strong analyst confidence against execution risks and current negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
